2SERUYS P W, DE FEYTER P, MACAYA C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial [J].JAMA, 2002, 287 (24) : 3215-3222. 被引量：1
3SCHWARTZ G G, OLSSON A G. EZEKOWITZ M D,et al. Effects of atorvastatin on early recurrent is chemic events in acute coronary syndromes. the MIRACL study: a randomized controlled trial [J]. JAMA, 2001, 285 (13) : 1711-1718. 被引量：1
4CANNON C P, BRAUNWALD E, MCCABE C H, et al. Intensive versus moderate lipid lowering with statlns after acute coronary syndromes [ J ]. N Engl J Med, 2004, 350 (15) : 1495-1504. 被引量：1
5NISSEN S E, TUZCU E M, SCHOENHAGEN P, et al. Effect of intensive compared with moderate hpid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial [J]. JAMA, 2004, 291 (9) : 1071-1080. 被引量：1
6LAROSA J C, GRUNDY S M, WATERS D D, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J]. N Engl J Med, 2005, 352 (14): 1425-1435. 被引量：1
7TOLMAN K G. The liver and lovastatin [ J]. Am J Cardiol, 2002, 89 (12) : 1374-1380. 被引量：1
8NEWMAN C B, PALMER G, SILBERSHATZ H, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9, 416 patients [ J ]. Am J Cardiol, 2003, 92 (6) : 670-676. 被引量：1
9HEART PROTECTION STUDY COLLABORATIVE GROUP. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial [J].Lancet, 2002, 360 (9326): 7-22. 被引量：1
10THOMPSON P D. CLARKSON P, KARAS R H. Statin-associated myopathy[J]. JAMA, 2003, 289 (13): 1681-1690. 被引量：1
2Scandinavian Simvastatin Survival Study Group. Ransonised trial of cholesterol lowering in 4444 subjects with coronary heart disease: The Scandinavian Simvastatin Survival Study(4S) . Lancet, 1994; 344;1383～ 1389. 被引量：1
3Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333(20): 1301 ～ 1307. 被引量：1
4Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996;335:1001 ～ 1009?A. 被引量：1
5The long - term intervention with Pravastatin in ischemic Disease (LIPID)Study Group. Prevention of cardiovascular events and death with pracastatin in patients with coronary heart disease and a broud range of initial cholesterol levels. N Engl J Med, 1998;339:1349 ～ 1357. 被引量：1
6Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA, 1998;279; 1615 ～ 1622. 被引量：1
7He Jiang, Gu DG, Reynolds K, et al.Serum Total and Lipoprotein Cholestrol Levels and Awareness, Treatment, and Control of Hypercholesterolemia in China. Circulation, 2004; 110: 405 ～ 411. 被引量：1
8Adult Treatment Panel Ⅲ: Executive summary of the third report of the National Cholesterol Education Program(NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA, 2001;285:2486～ 2497. 被引量：1
9Heart Protection Study Collaborative Group. MRC. BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo controlled trial. Lancet, 2002;360: 7～ 22. 被引量：1
10Nissen SE, Tuzcu E.M, Schoenhagen P, et al. Effect of intensive compared with moderate lipid- lowering therapy on progression of coronary atherosclerosis. JAMA, 2004; 291 (9): 107 1 ～ 1080. 被引量：1
